Trial Profile
A Phase 1 Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Subjects With Advanced Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 29 May 2018
Price :
$35
*
At a glance
- Drugs VS 4718 (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Verastem Oncology
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
- 24 Jan 2017 Status changed from recruiting to discontinued due to company's decision to de-prioritize 4718 development
- 04 Feb 2016 New trial record